FIGURE 8.

Comparison of simulated mean percent change (+ 1SD) in tumor diameter in response to pembrolizumab monotherapy (light blue) and pembrolizumab + ipilimumab combination therapy (black), by varying baseline tumor infiltrating lymphocytes (TILs) in the tumor microenvironment (TME) with combination therapy. We have defined cold as TIL less than 1.5% and hot as TIL greater than 5% and warm are intermediary TIL%. dSLD, change in sum of longest diameter; ORR, objective response rate; PD, progressive disease; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease; Sims, simulations